For this reason the discovery of oncogenic signalings responsible for the maintenance and expansion of CD44+/CD24− CSCs is crucial for the development of innovative-targeted therapies aimed to drastically reduce the recurrence and poor outcome of IBC tumors. The gene discussed is CD44; the disease is inflammatory breast carcinoma.